
A patient treated with the NG101 antibody during occupational therapy.
Photo Credit: Universitätsklinik Balgrist
Scientific Frontline: Extended "At a Glance" Summary: Anti-Nogo-A Therapy (NG101)
The Core Concept: Anti-Nogo-A therapy utilizes a novel monoclonal antibody, NG101, to stimulate the regeneration of damaged spinal cord tissue. By neutralizing growth-inhibiting proteins in the central nervous system, it enables severed nerve pathways to re-establish functional connections.
Key Distinction/Mechanism: Unlike traditional rehabilitation that relies on compensatory mechanisms, NG101 acts causally by targeting and blocking the Nogo-A protein found in myelin sheaths. Removing this molecular barrier allows surviving and newly formed nerve fibers to physically grow across lesion sites and reconnect with brain and motor control centers.
Origin/History: The Nogo-A protein and its inhibitory effects on neurite growth were discovered at the University of Zurich roughly 30 years ago. Extensive trials culminated in a multinational clinical study completed in late 2024, with pivotal MRI results published in May 2026 demonstrating objective structural healing.




.png)
.png)



.jpg)


.jpg)
